{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ferredoxine-NADP reductase : Questions médicales les plus fréquentes",
"headline": "Ferredoxine-NADP reductase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ferredoxine-NADP reductase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-31",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ferredoxine-NADP reductase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Oxidoreductases acting on sulfur group donors",
"url": "https://questionsmedicales.fr/mesh/D050862",
"about": {
"@type": "MedicalCondition",
"name": "Oxidoreductases acting on sulfur group donors",
"code": {
"@type": "MedicalCode",
"code": "D050862",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.667"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ferredoxine-NADP reductase",
"alternateName": "Ferredoxin-NADP Reductase",
"code": {
"@type": "MedicalCode",
"code": "D005287",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yoko Kimata-Ariga",
"url": "https://questionsmedicales.fr/author/Yoko%20Kimata-Ariga",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Yamaguchi 753-8515, Japan."
}
},
{
"@type": "Person",
"name": "Milagros Medina",
"url": "https://questionsmedicales.fr/author/Milagros%20Medina",
"affiliation": {
"@type": "Organization",
"name": "Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain; Instituto de Biocomputación y Física de Sistemas Complejos (Joint Units: BIFI-IQFR and GBsC-CSIC), Universidad de Zaragoza, 50018 Zaragoza, Spain. Electronic address: mmedina@unizar.es."
}
},
{
"@type": "Person",
"name": "Masayuki Miyata",
"url": "https://questionsmedicales.fr/author/Masayuki%20Miyata",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Chemistry, College of Agriculture, Graduate School of Sciences and Technology for Innovation, Yamaguchi University, Yoshida, Japan."
}
},
{
"@type": "Person",
"name": "Toshiharu Hase",
"url": "https://questionsmedicales.fr/author/Toshiharu%20Hase",
"affiliation": {
"@type": "Organization",
"name": "Division of Protein chemistry, Institute for Protein Research, Osaka University, Suita, Japan."
}
},
{
"@type": "Person",
"name": "Marta Martínez-Júlvez",
"url": "https://questionsmedicales.fr/author/Marta%20Mart%C3%ADnez-J%C3%BAlvez",
"affiliation": {
"@type": "Organization",
"name": "Departamento de Bioquímica y Biología Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, 50009 Zaragoza, Spain; Instituto de Biocomputación y Física de Sistemas Complejos (Joint Units: BIFI-IQFR and GBsC-CSIC), Universidad de Zaragoza, 50018 Zaragoza, Spain. Electronic address: mmartine@unizar.es."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Evidence of validity and reliability of Jumpo 2 and MyJump 2 for estimating vertical jump variables.",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36718456",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7717/peerj.14558"
}
},
{
"@type": "ScholarlyArticle",
"name": "Uric acid levels and their association with vascular dementia and Parkinson's disease dementia: a meta-analysis.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36690824",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10072-023-06620-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of Small versus Large-Bore Chest Drain in Pleural Infection: A Systematic Review and Meta-Analysis.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36693327",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1159/000529027"
}
},
{
"@type": "ScholarlyArticle",
"name": "ProteomicsML: An Online Platform for Community-Curated Data sets and Tutorials for Machine Learning in Proteomics.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36693629",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jproteome.2c00629"
}
},
{
"@type": "ScholarlyArticle",
"name": "Within-subject reliability of concurrent TMS-fMRI during a single session.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36694109",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/psyp.14252"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Oxidoreductases acting on sulfur group donors",
"item": "https://questionsmedicales.fr/mesh/D050862"
},
{
"@type": "ListItem",
"position": 6,
"name": "Ferredoxine-NADP reductase",
"item": "https://questionsmedicales.fr/mesh/D005287"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ferredoxine-NADP reductase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ferredoxine-NADP reductase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ferredoxine-NADP reductase",
"description": "Comment diagnostiquer une déficience en ferredoxine-NADP réductase ?\nQuels tests sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec cette enzyme ?\nY a-t-il des biomarqueurs associés à cette enzyme ?\nComment évaluer l'impact de l'alimentation sur l'enzyme ?",
"url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Reproducibility+of+Results&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ferredoxine-NADP reductase",
"description": "Quels sont les symptômes d'une déficience en ferredoxine-NADP réductase ?\nLa déficience peut-elle affecter la croissance des plantes ?\nY a-t-il des signes cliniques chez les animaux ?\nLes symptômes varient-ils selon les espèces ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Reproducibility+of+Results&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ferredoxine-NADP reductase",
"description": "Comment prévenir une déficience en ferredoxine-NADP réductase ?\nY a-t-il des pratiques agricoles recommandées ?\nLes tests de sol peuvent-ils aider à la prévention ?\nComment la sélection des semences influence-t-elle la prévention ?\nLes conditions climatiques affectent-elles la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Reproducibility+of+Results&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ferredoxine-NADP reductase",
"description": "Quels traitements existent pour la déficience en ferredoxine-NADP réductase ?\nLes thérapies géniques sont-elles une option ?\nComment l'alimentation peut-elle aider ?\nY a-t-il des médicaments spécifiques recommandés ?\nLes traitements varient-ils selon les espèces ?",
"url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Reproducibility+of+Results&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ferredoxine-NADP reductase",
"description": "Quelles complications peuvent survenir avec cette déficience ?\nLa déficience peut-elle affecter la reproduction des plantes ?\nY a-t-il des risques de maladies associées ?\nLes complications varient-elles selon les espèces ?\nComment les complications impactent-elles l'écosystème ?",
"url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Reproducibility+of+Results&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ferredoxine-NADP reductase",
"description": "Quels sont les facteurs de risque pour cette déficience ?\nLes variétés de plantes influencent-elles le risque ?\nLe stress hydrique est-il un facteur de risque ?\nLes maladies des plantes augmentent-elles le risque ?\nComment les pratiques agricoles affectent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D005287?mesh_terms=Reproducibility+of+Results&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en ferredoxine-NADP réductase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des analyses génétiques peuvent confirmer la déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité de l'enzyme ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests biochimiques mesurant l'activité de la ferredoxine-NADP réductase sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec cette enzyme ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fatigue, des troubles métaboliques ou des anomalies de croissance peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à cette enzyme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux de NADPH et de ferredoxine peuvent servir de biomarqueurs indirects."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact de l'alimentation sur l'enzyme ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études nutritionnelles peuvent aider à comprendre l'impact des nutriments sur l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en ferredoxine-NADP réductase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, troubles de la photosynthèse et anomalies métaboliques."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle affecter la croissance des plantes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner un retard de croissance et une photosynthèse inefficace."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cliniques chez les animaux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme une croissance réduite et des troubles métaboliques peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les espèces ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon les espèces végétales ou animales affectées."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver avec le temps si la déficience n'est pas traitée."
}
},
{
"@type": "Question",
"name": "Comment prévenir une déficience en ferredoxine-NADP réductase ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments peut aider à prévenir cette déficience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des pratiques agricoles recommandées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des engrais appropriés et gérer l'irrigation peut améliorer la santé des plantes."
}
},
{
"@type": "Question",
"name": "Les tests de sol peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests de sol réguliers peuvent identifier des carences nutritionnelles potentielles."
}
},
{
"@type": "Question",
"name": "Comment la sélection des semences influence-t-elle la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Choisir des semences résistantes peut réduire le risque de déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les conditions climatiques affectent-elles la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions climatiques extrêmes peuvent exacerber les déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour la déficience en ferredoxine-NADP réductase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique, mais des suppléments nutritionnels peuvent aider."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques sont-elles une option ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore disponible pour cette déficience."
}
},
{
"@type": "Question",
"name": "Comment l'alimentation peut-elle aider ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut soutenir l'activité enzymatique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des médicaments spécifiques recommandés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucun médicament spécifique n'est recommandé pour traiter cette déficience enzymatique."
}
},
{
"@type": "Question",
"name": "Les traitements varient-ils selon les espèces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent différer entre les plantes et les animaux selon les besoins."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec cette déficience ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et une croissance réduite."
}
},
{
"@type": "Question",
"name": "La déficience peut-elle affecter la reproduction des plantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner une réduction de la fertilité et des rendements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de maladies associées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies métaboliques peuvent survenir en raison de l'accumulation de métabolites."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon les espèces ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier selon les espèces végétales ou animales affectées."
}
},
{
"@type": "Question",
"name": "Comment les complications impactent-elles l'écosystème ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des déficiences généralisées peuvent affecter la chaîne alimentaire et la biodiversité."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour cette déficience ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs incluent une mauvaise nutrition, des conditions de sol défavorables et le stress environnemental."
}
},
{
"@type": "Question",
"name": "Les variétés de plantes influencent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines variétés sont plus susceptibles de développer des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Le stress hydrique est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress hydrique peut aggraver les déficiences en ferredoxine-NADP réductase."
}
},
{
"@type": "Question",
"name": "Les maladies des plantes augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies peuvent compromettre la santé des plantes et augmenter le risque de déficiences."
}
},
{
"@type": "Question",
"name": "Comment les pratiques agricoles affectent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des pratiques agricoles inadéquates peuvent augmenter le risque de déficiences enzymatiques."
}
}
]
}
]
}
We investigated the concurrent validity and test-retest reliability of the Jumpo 2 and MyJump 2 apps for estimating jump height, and the mean values of force, velocity, and power produced during count...
Physically active university aged men (...
Both apps provided a reliable estimate of jump height and the mean values of force, velocity, and power. Furthermore, estimates of jump height for CMJ and SJ and the mean force of the CMJ were valid. ...
Therefore, Jumpo 2 and MyJump 2 both provide a valid measure of jump height, but the remaining variables provided by these apps must be viewed with caution since the validity of force depends on jump ...
To explore the association between uric acid (UA) levels and vascular dementia (VaD) and Parkinson's disease dementia (PDD), a meta-analysis was conducted....
The relevant studies were identified by searching PubMed, Embase, Web of Science, and Cochrane Collaboration Database up to May 2022. Pooled analysis, sensitivity analysis, and publication bias examin...
Twelve studies with a total of 2097 subjects were included. The pooled analysis showed that UA levels were not associated with VaD (WMD = - 10.99 μmol/L, 95% CI (- 48.05, 26.07), P = 0.561) but were a...
UA levels are associated with PDD but not with VaD. This study will help to strengthen our knowledge of the pathophysiologies of VaD and PDD, and promote the development of prevention and treatment st...
Pleural infection represents a significant clinical challenge worldwide. Although prompt drainage of pleural fluid is thought to play a key role in pleural infection management, the optimal size of in...
The aim of this systematic review and meta-analysis was to summarize data on efficacy and complications of small-bore drain (SBD), defined as ≤14F, in comparison to large-bore drain (LBD) in patients ...
We searched MEDLINE and Embase for all studies reporting outcomes of interest published up to October 2021. Two authors reviewed selected full text to identify studies according to predefined eligibil...
Twelve original studies were included for qualitative analysis and 7 of these for quantitative analysis. The surgical referral rate of SBD and LBD were, respectively, 0.16 (95% confidence interval [CI...
This systematic review and meta-analysis provide the first synthesis of data on performance of SBD and LBD in management of pleural infection, and, overall, clinical outcomes and complications did not...
Data set acquisition and curation are often the most difficult and time-consuming parts of a machine learning endeavor. This is especially true for proteomics-based liquid chromatography (LC) coupled ...
Concurrent transcranial magnetic stimulation with functional MRI (concurrent TMS-fMRI) allows real-time causative probing of brain connectivity. However, technical challenges, safety, and tolerability...
Cognitive and behavioural responses to symptoms can worsen or maintain the severity of symptoms across long-term conditions (LTCs). Although the Cognitive and Behavioural Responses Questionnaire (CBRQ...
Psychometric validation study....
Confirmatory factor analysis (CFA) tested the factor structure of the CBRQ in two datasets from the CBRQ's original development; (chronic fatigue syndrome, N = 230; and multiple sclerosis, N = 221) an...
CFA revealed that a 7-or 8-factor structure had generally appropriate fit supporting the originally proposed 7 factors (Fear avoidance, Damage beliefs, Catastrophising, Embarrassment avoidance, Sympto...
The CBRQ and the shortened version were shown to be reliable and valid at assessing a range of cognitive and behavioural responses to symptoms, highlighting the multi-symptom, transdiagnostic properti...
Basic emergency management in urban and rural areas is a critical challenge, which can affect the pre-hospital mortality rate. Therefore, Non-hospital Healthcare Center (NHHC) must be prepared to mana...
This study was designed based on a sequential exploratory mixed- method in two phases, in each of which there are three steps. In the phase I, the literature systematic review and qualitative methods ...
In the phase I, primary version of the toolbar containing 134 items related to assessing the preparedness of NHHCs was generated. In the phase II, item reduction was applied and the final version of t...
This study provided a standard and valid toolbar that can be used to assess the preparedness of NHHCs to deliver initial emergency care....
Efforts to develop neuroimaging-based biomarkers in major depressive disorder (MDD), at the individual level, have been limited to date. As diagnostic criteria are currently symptom-based, MDD is conc...
We describe a consortium to quantify neuroanatomical and neurofunctional heterogeneity via the dimensions of novel multivariate coordinate system (COORDINATE-MDD). Utilizing imaging harmonization and ...
We are applying an iterative process by defining the neural dimensions that characterise deeply phenotyped samples and then testing the dimensions in novel samples to assess specificity and reliabilit...
We describe the consortium, imaging protocols and analytics using preliminary results. Our findings thus far demonstrate how datasets across many sites can be harmonized and constructively pooled to e...
This study aimed to explore the internal consistency and factor validity of the 13-item self-report questionnaire Parent-Patient Activation Measure (P-PAM) in a sample of parents of children with Atte...
In a cross-sectional study, 239 parents were recruited from four outpatient clinics of the Child and Adolescent Mental Health Services and completed the P-PAM along with demographic variables. The fac...
The fit indices suggest an acceptable two-factor model of P-PAM and show high internal consistency and reliability for both factors, indicating that the scale measures two concepts....
Our findings provide evidence for an acceptable factor structure and a high reliability of P-PAM as a measure of parent activation, suggesting that the theoretical factors reflect the construct of par...
This study aimed to investigate the multilevel factor structure of the therapist and client versions of the 12-item Working Alliance Inventory-Short Revised (WAI; Hatcher & Gillaspy, 2006) in the Unit...